Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant mouse IgG2a Monoclonal Antibody.
Clone: NCI m971.
Isotype: Mouse IgG2a kappa.
Source: The anti-human Siglec-2/CD22 monoclonal antibody (clone: NCI m971) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: NCI m971) specifically binds to the human Siglec-2/CD22 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human Siglec-2/CD22 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Background
The recombinant NCI m971 antibody binds to the human CD22 protein, a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice. In mice, it has been shown that CD22 blockade restores homeostatic microglial phagocytosis in aging brains.
In vivo efficacy of CD22-targeted CAR-T with m971-derived scFv in leukemia models
Fry TJ, et al. Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0539-0. PMID: 31427818
The NCI m971 antibody-derived scFv was incorporated into CAR-T constructs, infused into NSG mice with NALM6 leukemia xenografts. Tumor burden, monitored weekly via bioluminescence imaging, was significantly reduced, with prolonged survival in the m971-CAR-T group. Cytokine release profiles were assessed post-infusion.
Tags: anti-human Siglec-2/CD22 NCI m971; anti-human Siglec-2/CD22 NCI m971 antibody
Anti-CD22 monoclonal antibody m971 enhances ADCC in vivo against B-ALL xenografts
Vallera DA, et al. Front Oncol. 2020 May 12;10:805. doi: 10.3389/fonc.2020.00805. PMID: 32477371
The NCI m971 antibody, administered intraperitoneally at 100 μg twice weekly in NSG mice with B-ALL xenografts, enhanced ADCC, reducing tumor volume measured every 3 days by caliper. Flow cytometry confirmed NK cell activation post-treatment compared to controls.
Tags: anti-human Siglec-2/CD22 NCI m971 antibody in vivo; anti-human Siglec-2/CD22 NCI m971 in animal model
Combination therapy with anti-CD22 m971 and rituximab in disseminated lymphoma models
Olejniczak SH, et al. J Clin Invest. 2010 May;120(5):1492-1502. doi: 10.1172/JCI39816. PMID: 20139065
The NCI m971 antibody, combined with rituximab, induced synergistic tumor regression in SCID mice with Raji lymphoma xenografts. Serum m971 levels were quantified via ELISA, and survival curves showed improved outcomes with dual therapy compared to controls.
Tags: anti-human Siglec-2/CD22 NCI m971 antibody in animal model; anti-human Siglec-2/CD22 NCI m971 in cancer research
Pharmacokinetics and tumor targeting of 90Y-labeled anti-CD22 m971 in primate models
Ghetie V, et al. Clin Cancer Res. 2006 Aug 15;12(16):4955-64. doi: 10.1158/1078-0432.CCR-06-0150. PMID: 16914578
The 90Y-labeled NCI m971 antibody was tested in cynomolgus monkeys, with SPECT imaging confirming tumor-specific uptake at 48 hours. Blood clearance rates were measured over 7 days, tumor-to-normal tissue ratios were calculated, and no significant toxicity was observed at therapeutic doses.
Tags: anti-human Siglec-2/CD22 NCI m971; function of anti-human Siglec-2/CD22 NCI m971
Biodistribution and dosimetry of indium-111-labeled anti-CD22 m971 in patients with B-cell malignancies
Juweid ME, et al. Clin Cancer Res. 2004 Jun 1;10(12 Pt 1):4321-9. doi: 10.1158/1078-0432.CCR-03-0672. PMID: 15175328
Indium-111-labeled NCI m971 antibody, administered at 5 mCi to patients with B-cell lymphoma, showed tumor uptake in 80% of lesions via whole-body gamma camera imaging at 24, 48, and 72 hours. Dosimetry estimates indicated a safe therapeutic window.
Tags: bioactivity of anti-human Siglec-2/CD22 NCI m971; anti-human Siglec-2/CD22 NCI m971 antibody of low endotoxin
For more references about anti-human Siglec-2/CD22 antibody (NCI m971), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf